



Jonathan Silverstein
General Partner and Co-Head of Venture Capital
OrbiMed

Jonathan Silverstein is a General Partner and Co-Head of venture capital at OrbiMed, the world's largest asset management firm solely focused in healthcare with roughly \$15 billion in assets under management. OrbiMed manages over a dozen different hedge, venture capital, royalty and mutual funds. OrbiMed has over 100 employees throughout its 5 offices around the globe: New York, San Francisco, Mumbai, Shanghai and Tel Aviv. Four times (from 2012 to 2015), Mr. Silverstein was named to the Forbes Midas List, a list of the world's top 100 venture capitalists. Mr. Silverstein has a J.D. and an M.B.A. from the University of San Diego, and a B.A. in Economics from Denison University.

Currently, Mr. Silverstein is the Chairman of Intercept (ICPT), Cerapedics, and Audentes and is a board member of, Glaukos, DFine, Ascendis (ASND) and Roka Biosciences (ROKA).

Mr. Silverstein was formerly a chairman, director or observer of Arteaus (sold to LLY), Enobia (sold to ALXN), SuperDimension (sold to Covidien), Nxstage Medical (NXTM), Insulet Corporation (PODD), LifeCell (sold to KCI), Given Imaging (sold to Covidien), Cerexa (sold to FRX), Peninsula Pharmaceuticals (sold to JNJ), Predix (sold to EPIX), Avanir (AVNR), Orthovita (sold to SYK), Auxillium (AUXL), Bioenvision (sold to GENZ), Adiana (sold to HOLX), Civitas (sold to ACOR), Relypsa (RLYP) and Adolor (sold to CBST).